ibandronic acid has been researched along with Bone Neoplasms in 133 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (9.02) | 18.2507 |
| 2000's | 86 (64.66) | 29.6817 |
| 2010's | 29 (21.80) | 24.3611 |
| 2020's | 6 (4.51) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Chen, Z; Fu, W; Liu, G; Liu, H; Liu, L; Peng, D; Wang, Y; Xiang, K; Xu, T; Yang, S; Zhao, Y | 1 |
| Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M | 1 |
| Chen, Y; Hua, Q; Li, H; Wang, L; Xu, T | 1 |
| Chen, G; Chen, Y; Deng, J; Fan, D; Liu, H; Lu, Z; Mok, GSP; Yang, J | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Abbas, U; Axelrod, D; Bhasin, R; Bozzo, A; Deng, J; Deodat, M; Ghert, M; Masrouha, K; Sanger, S; Turcotte, R; Wariach, S; Wilson, D | 1 |
| Espey, R; Grimes, S; Heyburn, G; Kealey, WD | 1 |
| Han, J; Han, L; Liu, X; Wang, T; Zhang, H; Zhang, J; Zhang, L | 1 |
| Barrett-Lee, P; Fenlon, D; Griffiths, G; Harrop, E; Hood, K; Morris, J; Murray, N; Nelson, A; Sampson, C; Wheatley, D | 1 |
| Costa, L | 1 |
| Abraham, J; Barrett-Lee, P; Casbard, A; Coleman, R; Grieve, R; Griffiths, G; Hood, K; Murray, N; Simmonds, P; Timmins, H; Wheatley, D | 1 |
| Bray, C; Canney, P; Hannon, RA; Hopkins, C; Lewsley, LA; Macpherson, IR; Ritchie, DM | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| Bohlmann, MK; Luedders, DW; Rody, A; Steinhoff, J; Thill, M | 1 |
| Geng, CJ; Liang, Q; Liang, R; Meng, FY; Wu, N; Yuan, BY; Zhong, JH; Zhu, M | 1 |
| Cormack, FC; Gralow, JR; Jia, N; Najafian, B; Shiue, Z; Xie, B | 1 |
| Bloomfield, D; Forsyth, S; Hackshaw, A; Hoskin, P; Jitlal, M; Kirkwood, A; Mithal, N; Reczko, K; Sizer, B; Stratford, M; Sundar, S; Upadhyay, S; Wilson, P | 1 |
| Chung, YS; Kang, HC; Lee, T | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Jiang, Z; Song, S; Tian, J; Wang, R; Wang, T; Zhang, S | 1 |
| Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R | 1 |
| Armonis, BN; Migliorati, CA; Nicolatou-Galitis, O | 1 |
| Joensuu, TK | 1 |
| Bauss, F; Bergström, B | 1 |
| Colombel, M | 1 |
| Kalogeropoulou, C; Kardamakis, D; Vassiliou, V | 1 |
| Pecherstorfer, M | 2 |
| Bartl, R | 1 |
| Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
| Georgopoulou, AP; Hatzopoulos, A; Heras, P; Kritikos, K | 1 |
| Morgan, C; Wagstaff, J | 1 |
| Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F | 1 |
| Bergner, R; Diel, IJ; Kurth, AH; Maasberg, M; Meden, H; Sandermann, A; Sittig, HB | 1 |
| Biti, G; Bruni, A; Cipressi, S; De Luca Cardillo, C; Galardi, A; Livi, L; Meattini, I; Scotti, V | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Hatzopoulos, A; Heras, P; Heras, V; Karagiannis, S; Kritikos, K; Kritikos, N | 1 |
| Angst, R; Caspar, CB; Inauen, R; Schmieding, K; Steiner, R; Thürlimann, B; von Moos, R | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Abadie-Lacourtoisie, S; Dür, C; Frimat, L; Lefeuvre, C; Letessier, S; Lortholary, A; Mefti-Lacheraf, F; Morvan, P; Pivot, X; Pujade-Lauraine, E | 1 |
| Sittig, HB | 1 |
| Altundag, K; Dizdar, O; Eralp, Y; Karahoca, M; Komurcu, S; Kuzhan, O; Ozguroglu, M; Ozkok, S; Ozsaran, Z; Saip, P | 1 |
| Ignaczak, P; Jeka, S; Wegierska, M; Zalewska, J | 1 |
| Hiraga, T; Michigami, T; Mundy, GR; Niewolna, M; Nishimura, R; Williams, PJ; Yoneda, T | 1 |
| Elert, A; Heidenreich, A; Hofmann, R | 1 |
| DeClerck, YA; Pollack, H; Reynolds, CP; Scadeng, M; Shimada, H; Sohara, Y; Yamada, S; Ye, W | 1 |
| Heidenreich, A | 1 |
| Bergström, B; Body, JJ; Budde, M; Diel, IJ; Dornoff, W; Gorbunova, VA; Kreuser, ED; Lichinitser, MR | 2 |
| Bauss, F; Fischer, C; Krempien, B; Neudert, M; Seibel, MJ | 1 |
| Westermann, AM | 2 |
| Bell, R; Bergstrom, B; Body, JJ; Diel, IJ; Lazarev, A; Lichinitzer, M; Pecherstorfer, M; Tripathy, D | 1 |
| Adwan, H; Bäuerle, T; Berger, MR; Elazer, V; Golomb, G; Najajreh, Y | 1 |
| Rizzoli, R | 1 |
| Apffelstaedt, J; Bergstrom, B; Budde, M; Lazarev, A; Lichinitzer, M; MacLachlan, SA; Tripathy, D | 1 |
| Berenson, J; Hirschberg, R | 1 |
| Kurth, AH | 1 |
| Body, JJ; Dumon, JC; Mancini, I | 1 |
| Bell, R; Bergström, B; Body, JJ; Diel, IJ; Lazarev, AF; Lichinitser, MR; Pecherstorfer, M; Tripathy, D | 1 |
| Büyükçelik, A; Utkan, G; Yalçyn, B | 1 |
| Diel, IJ; Pecherstorfer, M | 1 |
| Rexer, H | 1 |
| Body, JJ; Diel, I; Tripathy A, D | 1 |
| Body, JJ; Heidenreich, A; Ohlmann, C | 1 |
| Bell, R; Coleman, R; Heidenreich, A | 1 |
| Hoskin, PJ | 1 |
| Heidenreich, A; Ohlmann, CH | 1 |
| Bauss, F; Body, JJ | 1 |
| Gennari, L | 1 |
| Harvey, HA | 1 |
| Bian, SG; Jiang, ZF; Li, LQ; Song, ST; Wang, T; Wang, YJ; Zhu, J | 1 |
| Khuri, F; Saba, N | 1 |
| Coleman, RE | 1 |
| Bergström, B; Body, JJ; Tripathy, D | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP | 2 |
| Lipton, A | 1 |
| Gordon, DH | 1 |
| Jackson, GH | 1 |
| Bell, R | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N | 1 |
| Diel, IJ | 1 |
| McCormack, PL; Plosker, GL | 1 |
| Guay, DR | 1 |
| Bergstrom, B; Body, JJ; Diel, IJ; Tripathy, D | 1 |
| Bauss, F; Body, JJ; Chaboteaux, C; Journé, F; Kinnaert, E; Magné, N | 1 |
| Cameron, D; Diel, I; Fallon, M | 1 |
| Christopoulos, C; Kalogeropoulou, C; Kardamakis, D; Leotsinides, M; Solomou, E; Vassiliou, V | 1 |
| Blair, JM; Brennan, K; Dunstan, CR; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Bergström, B; Cameron, D; McLachlan, SA; Murray, R; Tripathy, D | 1 |
| Bergström, B; Body, JJ; Diel, I; Pecherstorfer, M; Rivkin, S | 1 |
| Nagykálnai, T | 1 |
| Giannopoulou, E; Kalogeropoulou, C; Kardamakis, D; Leotsinidis, M; Tsota, I; Vassiliou, V | 1 |
| Bergström, B; Body, JJ; Garnero, P; Lichinitser, M; Tjulandin, S | 1 |
| Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W | 1 |
| Quesnel, M | 1 |
| Malden, NJ; Pai, AY | 1 |
| Hatzopoulos, A; Heras, P; Karagiannis, S; Kritikos, K; Mitsibounas, D | 1 |
| Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| McKeage, K; Plosker, GL | 1 |
| Angst, R; Bergstrom, B; Caspar, CB; Greil, R; Inauen, R; Pecherstorfer, M; Schmieding, K; Thürlimann, B; von Moos, R | 1 |
| Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Bauss, F; Ghilardi, JR; Halvorson, KG; Koewler, NJ; Mantyh, PW; Sevcik, MA; Sullivan, LJ | 1 |
| Kouloulias, V; Kouskouni, E; Mystakidou, K; Parpa, E; Stathopoulou, E; Vlahos, L | 1 |
| Coleman, R; Vinholes, J | 1 |
| Bauss, F; De Clerck, YA; Dunstan, C; Mundy, GR; Sasaki, A; Williams, PJ; Yoneda, T | 1 |
| Body, JJ; Buck, S; Huss, HJ; Ludwig, H; Pecherstorfer, M; Schlosser, K | 1 |
| Ziegler, J | 1 |
| Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S | 1 |
| Burckhardt, P | 1 |
| Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD | 1 |
| Balfour, JA; Dooley, M | 1 |
| Bauss, F; Boyce, BF; Dallas, MR; Dallas, SL; Garrett, IR; Mundy, GR; Oyajobi, BO; Radl, J | 1 |
| Black, C; Coleman, RE; Huss, H; Kanis, J; Purohit, OP; Quinn, KJ; Schlosser, K; Vinholes, JJ | 1 |
| Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Hiraga, T; Mundy, GR; Williams, PJ; Yoneda, T | 1 |
| Oppenkowski, R; Seegenschmiedt, MH | 1 |
| Bauss, F; Kim, SZ; Kurth, AA; Sedlmeyer, I; Shea, M | 1 |
40 review(s) available for ibandronic acid and Bone Neoplasms
| Article | Year |
|---|---|
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Ibandronic Acid; Lung Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Europe; Humans; Ibandronic Acid; Multiple Myeloma; Musculoskeletal Pain; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis, Focal Segmental; Humans; Ibandronic Acid; Prednisone; Proteinuria; Tacrolimus; Treatment Outcome | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Pain | 2008 |
Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Prostatic Neoplasms; Treatment Outcome | 2009 |
Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Pain; Quality of Life | 2010 |
Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.
Topics: Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid | 2012 |
Bisphosphonates in the management of metastatic prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Male; Pain; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Kidney Diseases | 2004 |
Ibandronate reduces skeletal morbidity in patients with breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Morbidity | 2004 |
Ibandronate in metastatic bone pain.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Pain; Urologic Neoplasms | 2004 |
Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Topics: Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Male | 2004 |
Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Neoplasms; Osteoporosis; Product Surveillance, Postmarketing; Risk Factors | 2004 |
Ibandronate in metastatic bone disease: a review of preclinical data.
Topics: Animals; Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid | 2005 |
Oral ibandronic acid.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Drugs, Investigational; Humans; Ibandronic Acid | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Multicenter Studies as Topic; Pain; Poisson Distribution; Randomized Controlled Trials as Topic | 2004 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Renal safety of ibandronate.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Kidney; Multiple Myeloma; Renal Insufficiency; Urologic Neoplasms | 2005 |
Efficacy of ibandronate in metastatic bone disease: review of clinical data.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Colorectal Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Multiple Myeloma; Treatment Outcome | 2005 |
Ibandronate: efficacy in the treatment of metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid | 2005 |
Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2006 |
Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Neoplasms; Osteoporosis | 2006 |
Ibandronate: its role in metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Pain; Randomized Controlled Trials as Topic | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
[The role of ibandronate in the daily oncological practice].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Medical Oncology; Quality of Life | 2006 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Ibandronate in oncology.
Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 1997 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate | 1998 |
Ibandronate.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
[Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
Topics: Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Humans; Ibandronic Acid; Male; Neoplasm Staging; Palliative Care; Prostatic Neoplasms; Radiotherapy; Survival Rate | 2001 |
29 trial(s) available for ibandronic acid and Bone Neoplasms
| Article | Year |
|---|---|
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Comparison of clinical effect in treatment of bone tumor between zoledronic acid needle and ibandronate needle.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Child; Female; Humans; Ibandronic Acid; Injections; Male; Middle Aged; Pain Measurement; Quality of Life; Young Adult; Zoledronic Acid | 2018 |
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comprehension; Diphosphonates; England; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pain Measurement; Patient Preference; Patient Satisfaction; Patients; Qualitative Research; Quality of Life; Time Factors; Treatment Outcome; Wales; Zoledronic Acid | 2013 |
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Zoledronic Acid | 2014 |
Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Peptides | 2015 |
Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Topics: Acute Disease; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Middle Aged; Prospective Studies; Zoledronic Acid | 2015 |
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Pain; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Time Factors; Treatment Outcome | 2015 |
Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome | 2009 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Pain; Pamidronate; Quality of Life | 2011 |
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney; Kidney Diseases; Longitudinal Studies; Middle Aged; Treatment Outcome | 2010 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Renal Insufficiency; Treatment Outcome | 2011 |
Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Pain; Pain Measurement; Prospective Studies; Treatment Outcome | 2012 |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Treatment Outcome | 2003 |
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Morbidity; Placebos; Risk Factors | 2004 |
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Morbidity; Pain; Placebos | 2004 |
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Long-Term Care; Middle Aged; Pain; Quality of Life; Survival Analysis; Treatment Outcome | 2004 |
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Middle Aged; Pain; Quality of Life; Statistics, Nonparametric | 2004 |
[Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Phosphorus; Pruritus | 2004 |
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Diseases; Middle Aged; Time Factors | 2006 |
Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Ibandronic Acid; Kidney; Middle Aged | 2006 |
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Leg; Middle Aged; Neoplasm Metastasis; Pulmonary Embolism; Survival Rate; Thrombosis; Time Factors; Treatment Outcome | 2006 |
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteocalcin; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2007 |
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Palliative Care; Pamidronate | 2008 |
Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Colorectal Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Pilot Projects | 2007 |
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Function Tests; Neoplasm Metastasis; Random Allocation; Time Factors; Treatment Outcome | 2008 |
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Neoplasms; Prognosis; Prospective Studies; Quality of Life | 2008 |
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged | 1996 |
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Biomarkers; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1999 |
64 other study(ies) available for ibandronic acid and Bone Neoplasms
| Article | Year |
|---|---|
Preparation, Characterization, and Preliminary Imaging Study of [
Topics: Animals; Bone Neoplasms; Humans; Ibandronic Acid; Mice; Mice, Nude; Rabbits; Radiopharmaceuticals; Theranostic Nanomedicine; Tissue Distribution | 2022 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid | 2022 |
177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases.
Topics: Bone Neoplasms; Humans; Ibandronic Acid; Male; Prostatic Neoplasms; Radiopharmaceuticals | 2023 |
Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases.
Topics: Bone Neoplasms; Humans; Ibandronic Acid; Positron-Emission Tomography; Radiometry; Tissue Distribution | 2023 |
The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Nails; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Femoral Fractures; Humans; Ibandronic Acid; Middle Aged | 2017 |
Which bisphosphonate to treat bone metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Zoledronic Acid | 2014 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Ibandronic Acid; Immunocompetence; Male; Neoplasm Metastasis; Osteolysis; Paclitaxel; Rats; Rats, Sprague-Dawley | 2015 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
Topics: Adult; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Peptides; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Data Interpretation, Statistical; Diphosphonates; Female; Gastrointestinal Agents; Humans; Ibandronic Acid; Imidazoles; Intention to Treat Analysis; Male; Medication Adherence; Mesalamine; Models, Statistical; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Treatment Outcome; Zoledronic Acid | 2017 |
Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis | 2008 |
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2008 |
[Prescription of bisphosphonates in prostate cancer].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid | 2008 |
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteogenesis; Pain Measurement; Pamidronate; Radiotherapy, Adjuvant; Zoledronic Acid | 2008 |
Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Ibandronic Acid; Pain | 2008 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid | 2010 |
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Prospective Studies; Severity of Illness Index | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
[Paget's disease: case report].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diagnosis, Differential; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteitis Deformans | 2011 |
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Heart Neoplasms; Humans; Ibandronic Acid; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured | 2002 |
Ibandronate in the treatment of prostate cancer associated painful osseous metastases.
Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Middle Aged; Pain; Prospective Studies; Prostatic Neoplasms | 2002 |
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.
Topics: Adrenal Glands; Animals; Apoptosis; Bone Neoplasms; Diphosphonates; Female; Femoral Neoplasms; Femur; Heart; Humans; Ibandronic Acid; Injections; Injections, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Osteoclasts; Osteolysis; Tail; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.
Topics: Animals; Apoptosis; Bone Density; Bone Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mammary Neoplasms, Experimental; Neoplasm Transplantation; Osteolysis; Rats; Rats, Nude; Rats, Sprague-Dawley; Transplantation, Heterologous | 2003 |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Incidence; Infusions, Intravenous | 2004 |
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Movement; Child; Colony-Forming Units Assay; Diphosphonates; Down-Regulation; Female; Green Fluorescent Proteins; Humans; Ibandronic Acid; Immunoglobulin G; Integrin-Binding Sialoprotein; Luminescent Proteins; Male; Oligonucleotides, Antisense; Organophosphates; Osteoblasts; Osteopontin; Osteosarcoma; Quaternary Ammonium Compounds; Sialoglycoproteins | 2004 |
Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Infusions, Intravenous | 2004 |
[Oral and parenteral forms of aminobisphosphonate].
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Colorectal Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Osteolysis; Spinal Neoplasms | 2004 |
Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
Topics: Adult; Aged; Bone Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Narcotics; Pain; Pilot Projects; Quality of Life | 2004 |
[Bone metastases in breast carcinoma. Bisphosphonate protects from complications].
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Time Factors | 2004 |
The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Treatment Outcome | 2004 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; Pain; Patient Selection; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
Targeting Breast Cancer with Care. Proceedings of a meeting. Prague, Czech Republic, February 2004.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid | 2004 |
Managing metastatic bone disease: three case studies.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms, Second Primary; Palliative Care; Prostatic Neoplasms | 2004 |
The RIB trial.
Topics: Biomarkers; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Pain | 2004 |
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Ethics, Medical; Female; Humans; Ibandronic Acid; Placebos; Randomized Controlled Trials as Topic | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid | 2005 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 2006 |
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Survival; Combined Modality Therapy; Diphosphonates; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ibandronic Acid; Radiotherapy Dosage; Tumor Cells, Cultured | 2006 |
Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment.
Topics: Aged; Analgesics, Opioid; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Pain; Pain Measurement; Pilot Projects; Prospective Studies; Statistics, Nonparametric | 2007 |
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Ibandronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoprotegerin; Tibia; Xenograft Model Antitumor Assays | 2007 |
A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.
Topics: Adult; Aged; Analgesics, Opioid; Bone Density; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Pain; Quality of Life | 2007 |
[Nurse's role in the home management of patients with breast cancer and bone metastases].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Protocols; Community Health Nursing; Diphosphonates; Drug Monitoring; Home Care Services; Home Infusion Therapy; Humans; Ibandronic Acid; Nurse's Role; Nursing Assessment | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Diphosphonates; Eccrine Glands; Epirubicin; Fluorouracil; Humans; Ibandronic Acid; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Radiotherapy; Sweat Gland Neoplasms; Tamoxifen; Tomography, X-Ray Computed | 2007 |
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Topics: Administration, Oral; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Osteocalcin; Peptides; Procollagen; Prognosis; Sensitivity and Specificity; Zoledronic Acid | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2008 |
Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
Topics: Animals; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Ibandronic Acid; Injections, Intravenous; Male; Mice; Mice, Inbred C3H; Osteolysis; Osteosarcoma; Pain; Pain Measurement; Treatment Outcome | 2008 |
The management of bone metastases.
Topics: Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Middle Aged; Pain | 1995 |
[Bisphosphonates in radiotherapy].
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Radiotherapy | 1997 |
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Survival; Diphosphonates; Female; Genetic Therapy; Heart Ventricles; Humans; Ibandronic Acid; Mice; Mice, Nude; Neoplasm Invasiveness; Osteolysis; Protein Biosynthesis; Tibia; Tissue Inhibitor of Metalloproteinase-2; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured | 1997 |
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Ibandronic Acid; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasms, Experimental | 1999 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mice; Mice, Inbred BALB C; Osteoclasts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Mammary Neoplasms, Experimental; Osteolysis; Rats; Rats, Sprague-Dawley; Sarcoma, Experimental | 2002 |